# ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism

> **NCT00135304** · PHASE4 · COMPLETED · sponsor: **Amgen** · enrollment: 170 (actual)

## Conditions studied

- Secondary Hyperparathyroidism

## Interventions

- **DRUG:** Sensipar®
- **DRUG:** Vitamin D

## Key facts

- **NCT ID:** NCT00135304
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2006-10
- **Final completion:** 2006-12
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2014-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00135304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00135304, "ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT00135304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*